

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

ORASURE TECHNOLOGIES INC

Form 8-K

November 07, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 7, 2002

OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

DELAWARE	1-10492	36-4370966
(State or Other	(Commission	(I.R.S. Employer
Jurisdiction	file	Identification
of Incorporation or	number)	Number)
Organization)		

150 Webster Street
Bethlehem, Pennsylvania 18015
(Address of principal executive offices)

(610) 882-1820
(Registrant's telephone number, including area code)

Item 5 - Other Events.

OraSure Technologies, Inc. (the "Company") issued a press release on November 7, 2002, announcing the receipt of U.S. Food and Drug Administration ("FDA") approval of the Company's OraQuick(R) Rapid HIV-1 Antibody Test for the detection of HIV-1 antibodies in finger-stick whole blood samples. A copy of the press release is attached to this Report as Exhibit 99 and is incorporated herein by reference.

Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OraSure Technologies, Inc.

Date: November 7, 2002

By: /s/ Jack E. Jerrett

Jack E. Jerrett
Vice President, General Counsel

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

and Secretary

EXHIBIT INDEX

Exhibit

99

Press Release issued November 7, 2002 by OraSure Technologies announcing the receipt of U.S. Food and Drug Administration ("FDA") approval of the Company's OraQuick(R) Rapid HIV-1 Antibody Test for the detection of HIV-1 antibodies in finger-stick whole blood samples.